Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 6/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | IGF1R | P08069 | 4/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 5/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220647 | 0.87 | PAK4 (0.57) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL3849950 | 0.84 | GRK6 (0.42) | PAK4PLK4PIK3C3AURKAAURKB | |
| SCHEMBL19833663 | 0.83 | PIK3C3 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL22079284 | 0.81 | PAK4 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL4913165 | 0.81 | PIK3C3 (0.45) | PAK4PLK4MEN1KMT2APIK3C3 | |
| SCHEMBL4788903 | 0.81 | PAK4 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL3993234 | 0.81 | PAK4 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL24350501 | 0.80 | PIK3C3 (0.54) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL4116079 | 0.80 | PAK4 (0.48) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL18297024 | 0.80 | PIK3C3 (0.47) | PAK4PLK4MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234222-B2 | Piperazine amide derivative, preparation method therefor, and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| US-20240417386-A1 | INHIBITORS OF RET | MIDCAP FINANCIAL TRUST | 2024-12-19 | — | — | US | disclosed |
| CN-113135896-B | Methylpyrazole derivatives as RET inhibitors | 正大天晴药业集团股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4331585-A2 | INHIBITORS OF RET | Blueprint Medicines Corporation (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4292594-A2 | INHIBITORS OF RET | Blueprint Medicines Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3371171-B1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3371171-B1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230295174-A1 | SALT AND CRYSTAL FORM OF PYRIMIDINE COMPOUND, AND PREPARATION METHODS THEREFOR | ELLIPSES PHARMA LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| CN-111484479-B | Azacyclic compounds, pharmaceutical compositions containing the same, and methods of making and using the same | 四川科伦博泰生物医药股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-111423416-B | Inhibitors of RET | 缆图药品公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-1869032-B1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-1869032-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1863797-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006106307-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006100461-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
| EP-1678169-A1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | IGF1R, TYMP, IGFBP1 | PAK4 2522/4885PLK4 3448/4885MEN1 1371/4885 |
| US-20240417386-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | PAK4 121/4885PLK4 3236/4885MEN1 376/4885 |
| US-12234222-B2 | Piperazine amide derivative, preparation method therefor, and use thereof in medicine | WEE1, WEE2, RET | PAK4 169/4885PLK4 1884/4885MEN1 491/4885 |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | IGF1R, IGFBP1, GPR119 | PAK4 2162/4885PLK4 2334/4885MEN1 2736/4885 |
| US-20230295174-A1 | SALT AND CRYSTAL FORM OF PYRIMIDINE COMPOUND, AND PREPARATION METHODS THEREFOR | WEE1, TYMP, TYMS | PAK4 1307/4885PLK4 2717/4885MEN1 1400/4885 |
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | IGF1R, IGFBP1, IGFBP2 | PAK4 2560/4885PLK4 3510/4885MEN1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.